This activity was originally presented at the 2026 HOPA
Annual Conference in New Orleans, LA.
The treatment landscape for B-cell non-Hodgkin lymphomas, particularly diffuse large B-cell lymphoma and follicular lymphoma, has evolved rapidly with the introduction of bispecific antibodies (BsAbs). These immunotherapies are increasingly incorporated into practice, raising key questions around sequencing, comparative efficacy, and real-world implementation. As BsAbs transition from inpatient to outpatient and community oncology settings, they offer opportunities to expand access while introducing clinical and operational complexities, including standardized monitoring and management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Oncology pharmacists play a critical role across this continuum by interpreting emerging evidence, developing step-up dosing and toxicity management protocols, and operationalizing label-directed safety and monitoring requirements. This multidisciplinary panel will examine practical strategies to support evidence-based decision-making, optimize outpatient workflows, and safely implement BsAbs in patients with DLBCL and follicular lymphoma through case-based discussion.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 15, 2026
Expiration date: April 15, 2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Apply emerging clinical evidence of bispecific antibodies in diffuse large B-cell lymphoma and follicular lymphoma to guide pharmacist-driven integration into evolving sequencing pathways
- Prioritize multidisciplinary approaches to adverse effect recognition and escalation in outpatient settings, ensuring pharmacists play a central role in patient education, toxicity grading, and continuity of care
- Employ best practices for pharmacist-led operational integration, including order set builds, compounding/verification, and infusion workflows, to reduce error risk and ensure patient safety
Samantha Maples, PharmD, BCOP
Clinical Pharmacy Specialist Supervisor
Hematology and Cellular Therapy
Allegheny Health Network
Pittsburgh, PA
Sara Moran Smith, PharmD, BCOP
Oncology Pharmacy Program Manager
Residency Program Director - PGY2 Oncology
Allina Health
Minneapolis, MN
Javier Munoz, MD, MS, MBA
Director, Lymphoma Program
Mayo Clinic
Scottsdale, AZ
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-068-H01-P. The activity is available for CE credit through April 15, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Samantha Maples, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:
Consultant: Bristol Myers Squibb, Janssen
Sara Moran Smith, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:
Consultant: Sanofi
Speakers Bureau: Karyopharm, Regeneron
Javier Munoz, MD, MS, MBA, has the following relevant financial relationships with ineligible companies to disclose:
Grant/Research Support: Bayer, Celgene, Genentech, Gilead/Kite, Incyte, Merck, Pharmacyclics, Portola
Consultant: Bayer, BeiGene, Celgene/BMS, Gilead/Kite, Janssen, Kyowa, Pharmacyclics/AbbVie, Pfizer
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here